APO Research
Talk to an analyst

APO RESEARCH · REPORT

Central Nervous System (CNS) Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Central Nervous System (CNS) Drug Market Outlook and Growth Opportunities 2026

31 December 2025191 pages

Choose your research edition.

Industry ResearchCentral Nervous System (CNS) Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Central Nervous System (CNS) Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Central Nervous System (CNS) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Central Nervous System (CNS) Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Central Nervous System (CNS) Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Central Nervous System (CNS) Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Central Nervous System (CNS) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Central Nervous System (CNS) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Central Nervous System (CNS) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Central Nervous System (CNS) Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Central Nervous System (CNS) Drug market include Tekeda, Teva, Shanghai Fosun, Johnson & Johnson, Novartis AG, Roche, Eli Lilly, Jiangsu Nhwa Pharmaceutical Co., Ltd. and Pfizer Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Central Nervous System (CNS) Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Central Nervous System (CNS) Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Central Nervous System (CNS) Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Central Nervous System (CNS) Drug market.

Central Nervous System (CNS) Drug Segment by Company

Tekeda

Teva

Shanghai Fosun

Johnson & Johnson

Novartis AG

Roche

Eli Lilly

Jiangsu Nhwa Pharmaceutical Co., Ltd.

Pfizer Inc

GSK

UCB

Otsuka Pharmaceutical Co., Ltd

Boehringer Ingelheim

Biogen Inc

Central Nervous System (CNS) Drug Segment by Type

Prescription Drugs

OTC

Central Nervous System (CNS) Drug Segment by Application

Epilepsy Drugs

MS Therapeutics

Antipsychotic Drugs

Depression Drugs

Others

Central Nervous System (CNS) Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Central Nervous System (CNS) Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Central Nervous System (CNS) Drug key companies, revenue, market share, and recent developments.

3. To split the Central Nervous System (CNS) Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Central Nervous System (CNS) Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Central Nervous System (CNS) Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Central Nervous System (CNS) Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Central Nervous System (CNS) Drug industry.

Chapter 3: Detailed analysis of Central Nervous System (CNS) Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Central Nervous System (CNS) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Central Nervous System (CNS) Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Central Nervous System (CNS) Drug Industry Trends Table 2. Central Nervous System (CNS) Drug Industry Drivers Table 3. Central Nervous System (CNS) Drug Industry Opportunities and Challenges Table 4. Central Nervous System (CNS) Drug Industry Restraints Table 5. Global Central Nervous System (CNS) Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Central Nervous System (CNS) Drug Revenue Share by Company (2021-2026) Table 7. Global Central Nervous System (CNS) Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Central Nervous System (CNS) Drug Key Company Manufacturing Base & Headquarters Table 9. Global Central Nervous System (CNS) Drug Company, Product Type & Application Table 10. Global Central Nervous System (CNS) Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Central Nervous System (CNS) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Prescription Drugs Table 15. Significant Companies of OTC Table 16. Global Central Nervous System (CNS) Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Central Nervous System (CNS) Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Central Nervous System (CNS) Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Central Nervous System (CNS) Drug Sales Value Share by Type (2021-2026) Table 20. Global Central Nervous System (CNS) Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Epilepsy Drugs Table 22. Significant Companies of MS Therapeutics Table 23. Significant Companies of Antipsychotic Drugs Table 24. Significant Companies of Depression Drugs Table 25. Significant Companies of Others Table 26. Global Central Nervous System (CNS) Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Central Nervous System (CNS) Drug Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Central Nervous System (CNS) Drug Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Central Nervous System (CNS) Drug Sales Value Share by Application (2021-2026) Table 30. Global Central Nervous System (CNS) Drug Sales Value Share by Application (2027-2032) Table 31. Global Central Nervous System (CNS) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Central Nervous System (CNS) Drug Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Central Nervous System (CNS) Drug Sales Value Share by Region (2021-2026) Table 34. Global Central Nervous System (CNS) Drug Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Central Nervous System (CNS) Drug Sales Value Share by Region (2027-2032) Table 36. Global Central Nervous System (CNS) Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Central Nervous System (CNS) Drug Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Central Nervous System (CNS) Drug Sales Value Market Share by Country (2021-2026) Table 39. Global Central Nervous System (CNS) Drug Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Central Nervous System (CNS) Drug Sales Value Market Share by Country (2027-2032) Table 41. Tekeda Company Information Table 42. Tekeda Business Overview Table 43. Tekeda Central Nervous System (CNS) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Tekeda Central Nervous System (CNS) Drug Product Portfolio Table 45. Tekeda Recent Development Table 46. Teva Company Information Table 47. Teva Business Overview Table 48. Teva Central Nervous System (CNS) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Teva Central Nervous System (CNS) Drug Product Portfolio Table 50. Teva Recent Development Table 51. Shanghai Fosun Company Information Table 52. Shanghai Fosun Business Overview Table 53. Shanghai Fosun Central Nervous System (CNS) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Shanghai Fosun Central Nervous System (CNS) Drug Product Portfolio Table 55. Shanghai Fosun Recent Development Table 56. Johnson & Johnson Company Information Table 57. Johnson & Johnson Business Overview Table 58. Johnson & Johnson Central Nervous System (CNS) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Johnson & Johnson Central Nervous System (CNS) Drug Product Portfolio Table 60. Johnson & Johnson Recent Development Table 61. Novartis AG Company Information Table 62. Novartis AG Business Overview Table 63. Novartis AG Central Nervous System (CNS) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Novartis AG Central Nervous System (CNS) Drug Product Portfolio Table 65. Novartis AG Recent Development Table 66. Roche Company Information Table 67. Roche Business Overview Table 68. Roche Central Nervous System (CNS) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Roche Central Nervous System (CNS) Drug Product Portfolio Table 70. Roche Recent Development Table 71. Eli Lilly Company Information Table 72. Eli Lilly Business Overview Table 73. Eli Lilly Central Nervous System (CNS) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Eli Lilly Central Nervous System (CNS) Drug Product Portfolio Table 75. Eli Lilly Recent Development Table 76. Jiangsu Nhwa Pharmaceutical Co., Ltd. Company Information Table 77. Jiangsu Nhwa Pharmaceutical Co., Ltd. Business Overview Table 78. Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Product Portfolio Table 80. Jiangsu Nhwa Pharmaceutical Co., Ltd. Recent Development Table 81. Pfizer Inc Company Information Table 82. Pfizer Inc Business Overview Table 83. Pfizer Inc Central Nervous System (CNS) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Pfizer Inc Central Nervous System (CNS) Drug Product Portfolio Table 85. Pfizer Inc Recent Development Table 86. GSK Company Information Table 87. GSK Business Overview Table 88. GSK Central Nervous System (CNS) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. GSK Central Nervous System (CNS) Drug Product Portfolio Table 90. GSK Recent Development Table 91. UCB Company Information Table 92. UCB Business Overview Table 93. UCB Central Nervous System (CNS) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. UCB Central Nervous System (CNS) Drug Product Portfolio Table 95. UCB Recent Development Table 96. Otsuka Pharmaceutical Co., Ltd Company Information Table 97. Otsuka Pharmaceutical Co., Ltd Business Overview Table 98. Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Product Portfolio Table 100. Otsuka Pharmaceutical Co., Ltd Recent Development Table 101. Boehringer Ingelheim Company Information Table 102. Boehringer Ingelheim Business Overview Table 103. Boehringer Ingelheim Central Nervous System (CNS) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Boehringer Ingelheim Central Nervous System (CNS) Drug Product Portfolio Table 105. Boehringer Ingelheim Recent Development Table 106. Biogen Inc Company Information Table 107. Biogen Inc Business Overview Table 108. Biogen Inc Central Nervous System (CNS) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Biogen Inc Central Nervous System (CNS) Drug Product Portfolio Table 110. Biogen Inc Recent Development Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Central Nervous System (CNS) Drug Product Image Figure 2. Global Central Nervous System (CNS) Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Central Nervous System (CNS) Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Central Nervous System (CNS) Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Prescription Drugs Image Figure 8. OTC Image Figure 9. Global Central Nervous System (CNS) Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Central Nervous System (CNS) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Central Nervous System (CNS) Drug Sales Value Share by Type (2021-2032) Figure 12. Epilepsy Drugs Image Figure 13. MS Therapeutics Image Figure 14. Antipsychotic Drugs Image Figure 15. Depression Drugs Image Figure 16. Others Image Figure 17. Global Central Nervous System (CNS) Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Central Nervous System (CNS) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Central Nervous System (CNS) Drug Sales Value Share by Application (2021-2032) Figure 20. Global Central Nervous System (CNS) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Central Nervous System (CNS) Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Central Nervous System (CNS) Drug Sales Value (2021-2032) & (US$ Million) Figure 23. North America Central Nervous System (CNS) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Central Nervous System (CNS) Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Central Nervous System (CNS) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Central Nervous System (CNS) Drug Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Central Nervous System (CNS) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Central Nervous System (CNS) Drug Sales Value (2021-2032) & (US$ Million) Figure 29. South America Central Nervous System (CNS) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Central Nervous System (CNS) Drug Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Central Nervous System (CNS) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Prescription Drugs
  • OTC
Applications
  • Epilepsy Drugs
  • MS Therapeutics
  • Antipsychotic Drugs
  • Depression Drugs
  • Others
Companies covered
  • Tekeda
  • Teva
  • Shanghai Fosun
  • Johnson & Johnson
  • Novartis AG
  • Roche
  • Eli Lilly
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • Pfizer Inc
  • GSK
  • UCB
  • Otsuka Pharmaceutical Co., Ltd
  • Boehringer Ingelheim
  • Biogen Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Central Nervous System (CNS) Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Central Nervous System (CNS) Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Central Nervous System (CNS) Drug Market Dynamics
  1. 2.1 Central Nervous System (CNS) Drug Industry Trends
  2. 2.2 Central Nervous System (CNS) Drug Industry Drivers
  3. 2.3 Central Nervous System (CNS) Drug Industry Opportunities and Challenges
  4. 2.4 Central Nervous System (CNS) Drug Industry Restraints
3 Central Nervous System (CNS) Drug Market by Company
  1. 3.1 Global Central Nervous System (CNS) Drug Company Revenue Ranking in 2025
  2. 3.2 Global Central Nervous System (CNS) Drug Revenue by Company (2021-2026)
  3. 3.3 Global Central Nervous System (CNS) Drug Company Ranking (2024-2026)
  4. 3.4 Global Central Nervous System (CNS) Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Central Nervous System (CNS) Drug Company Product Type and Application
  6. 3.6 Global Central Nervous System (CNS) Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Central Nervous System (CNS) Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Central Nervous System (CNS) Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Central Nervous System (CNS) Drug Market by Type
  1. 4.1 Central Nervous System (CNS) Drug Type Introduction
  2. 4.1.1 Prescription Drugs
  3. 4.1.2 OTC
  4. 4.2 Global Central Nervous System (CNS) Drug Sales Value by Type
  5. 4.2.1 Global Central Nervous System (CNS) Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Central Nervous System (CNS) Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Central Nervous System (CNS) Drug Sales Value Share by Type (2021-2032)
5 Central Nervous System (CNS) Drug Market by Application
  1. 5.1 Central Nervous System (CNS) Drug Application Introduction
  2. 5.1.1 Epilepsy Drugs
  3. 5.1.2 MS Therapeutics
  4. 5.1.3 Antipsychotic Drugs
  5. 5.1.4 Depression Drugs
  6. 5.1.5 Others
  7. 5.2 Global Central Nervous System (CNS) Drug Sales Value by Application
  8. 5.2.1 Global Central Nervous System (CNS) Drug Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Central Nervous System (CNS) Drug Sales Value by Application (2021-2032)
  10. 5.2.3 Global Central Nervous System (CNS) Drug Sales Value Share by Application (2021-2032)
6 Central Nervous System (CNS) Drug Regional Value Analysis
  1. 6.1 Global Central Nervous System (CNS) Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Central Nervous System (CNS) Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Central Nervous System (CNS) Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Central Nervous System (CNS) Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Central Nervous System (CNS) Drug Sales Value (2021-2032)
  7. 6.3.2 North America Central Nervous System (CNS) Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Central Nervous System (CNS) Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Central Nervous System (CNS) Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Central Nervous System (CNS) Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Central Nervous System (CNS) Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Central Nervous System (CNS) Drug Sales Value (2021-2032)
  16. 6.6.2 South America Central Nervous System (CNS) Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Central Nervous System (CNS) Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Central Nervous System (CNS) Drug Sales Value Share by Country, 2025 VS 2032
7 Central Nervous System (CNS) Drug Country-level Value Analysis
  1. 7.1 Global Central Nervous System (CNS) Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Central Nervous System (CNS) Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Central Nervous System (CNS) Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Central Nervous System (CNS) Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Central Nervous System (CNS) Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Central Nervous System (CNS) Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Central Nervous System (CNS) Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Tekeda
  2. 8.1.1 Tekeda Company Information
  3. 8.1.2 Tekeda Business Overview
  4. 8.1.3 Tekeda Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Tekeda Central Nervous System (CNS) Drug Product Portfolio
  6. 8.1.5 Tekeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Central Nervous System (CNS) Drug Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Shanghai Fosun
  14. 8.3.1 Shanghai Fosun Company Information
  15. 8.3.2 Shanghai Fosun Business Overview
  16. 8.3.3 Shanghai Fosun Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Fosun Central Nervous System (CNS) Drug Product Portfolio
  18. 8.3.5 Shanghai Fosun Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Central Nervous System (CNS) Drug Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Novartis AG
  26. 8.5.1 Novartis AG Company Information
  27. 8.5.2 Novartis AG Business Overview
  28. 8.5.3 Novartis AG Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis AG Central Nervous System (CNS) Drug Product Portfolio
  30. 8.5.5 Novartis AG Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Central Nervous System (CNS) Drug Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly Central Nervous System (CNS) Drug Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
  43. 8.8 Jiangsu Nhwa Pharmaceutical Co., Ltd.
  44. 8.8.1 Jiangsu Nhwa Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Jiangsu Nhwa Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Product Portfolio
  48. 8.8.5 Jiangsu Nhwa Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Pfizer Inc
  50. 8.9.1 Pfizer Inc Company Information
  51. 8.9.2 Pfizer Inc Business Overview
  52. 8.9.3 Pfizer Inc Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Inc Central Nervous System (CNS) Drug Product Portfolio
  54. 8.9.5 Pfizer Inc Recent Developments
  55. 8.10 GSK
  56. 8.10.1 GSK Company Information
  57. 8.10.2 GSK Business Overview
  58. 8.10.3 GSK Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GSK Central Nervous System (CNS) Drug Product Portfolio
  60. 8.10.5 GSK Recent Developments
  61. 8.11 UCB
  62. 8.11.1 UCB Company Information
  63. 8.11.2 UCB Business Overview
  64. 8.11.3 UCB Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 UCB Central Nervous System (CNS) Drug Product Portfolio
  66. 8.11.5 UCB Recent Developments
  67. 8.12 Otsuka Pharmaceutical Co., Ltd
  68. 8.12.1 Otsuka Pharmaceutical Co., Ltd Company Information
  69. 8.12.2 Otsuka Pharmaceutical Co., Ltd Business Overview
  70. 8.12.3 Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Product Portfolio
  72. 8.12.5 Otsuka Pharmaceutical Co., Ltd Recent Developments
  73. 8.13 Boehringer Ingelheim
  74. 8.13.1 Boehringer Ingelheim Company Information
  75. 8.13.2 Boehringer Ingelheim Business Overview
  76. 8.13.3 Boehringer Ingelheim Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Boehringer Ingelheim Central Nervous System (CNS) Drug Product Portfolio
  78. 8.13.5 Boehringer Ingelheim Recent Developments
  79. 8.14 Biogen Inc
  80. 8.14.1 Biogen Inc Company Information
  81. 8.14.2 Biogen Inc Business Overview
  82. 8.14.3 Biogen Inc Central Nervous System (CNS) Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Biogen Inc Central Nervous System (CNS) Drug Product Portfolio
  84. 8.14.5 Biogen Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst